When.com Web Search

  1. Ads

    related to: stroke statin guidelines

Search results

  1. Results From The WOW.Com Content Network
  2. 17 million US adults may no longer receive statin therapy for ...

    www.aol.com/17-million-us-adults-may-160000273.html

    These guidelines recommend statin therapy for adults between forty and seventy-five who have diabetes, high cholesterol levels, or an estimated 10-year atherosclerotic cardiovascular disease risk ...

  3. Statin - Wikipedia

    en.wikipedia.org/wiki/Statin

    Guidelines by the American College of Cardiology and the American Heart Association recommend statin treatment for primary prevention of cardiovascular disease in adults with LDL cholesterol ≥ 190 mg/dL (4.9 mmol/L) or those with diabetes, age 40–75 with LDL-C 70–190 mg/dL (1.8–4.9 mmol/dL); or in those with a 10-year risk of developing ...

  4. Your biggest questions about strokes, answered - AOL

    www.aol.com/biggest-questions-strokes-answered...

    A stroke is like the brain’s version of a heart attack — and is also life-threatening. ... high cholesterol, and diabetes. ... The American Heart Association’s most recent guidelines for ...

  5. Lifestyle changes key to preventing strokes, new guidelines ...

    www.aol.com/stroke-prevention-guidelines...

    Latest stroke prevention guidelines highlight the importance of lifestyle interventions for cardiovascular health and managing conditions such as type 2 diabetes and high blood pressure.

  6. JUPITER trial - Wikipedia

    en.wikipedia.org/wiki/JUPITER_trial

    JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP).

  7. AIM-HIGH (trial) - Wikipedia

    en.wikipedia.org/wiki/AIM-HIGH_(trial)

    Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (also known as AIM-HIGH) was a randomized control trial designed to assess the efficacy of niacin (extended-release) added to statin therapy in reducing cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD).